Pfizer Inc. $PFE Shares Bought by Capital International Ltd. CA

Posted by Francis Steltz on Jun 7th, 2026

Capital International Ltd. CA raised its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 58.4% in the 4th quarter, HoldingsChannel reports. The fund owned 417,499 shares of the biopharmaceutical company’s stock after acquiring an additional 154,008 shares during the period. Capital International Ltd. CA’s holdings in Pfizer were worth $10,396,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Triad Wealth Partners LLC raised its holdings in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 386 shares during the last quarter. ETF Store Inc. raised its holdings in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 396 shares during the last quarter. Mattern Wealth Management LLC grew its stake in shares of Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 400 shares during the period. Pines Wealth Management LLC grew its stake in shares of Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 400 shares during the period. Finally, Pathway Financial Advisers LLC grew its stake in shares of Pfizer by 0.9% during the 4th quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock valued at $1,155,000 after buying an additional 403 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.4%

Shares of NYSE PFE opened at $26.04 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $148.43 billion, a PE ratio of 19.88 and a beta of 0.34. The firm has a fifty day moving average of $26.62 and a 200-day moving average of $26.29. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s payout ratio is presently 131.30%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Finally, CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.82.

Read Our Latest Stock Report on PFE

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.